Himadri Speciality Chemicals shares surged as much as 6% in Monday's trading session, hitting a fresh 52-week high of ₹786.85 on the NSE after reporting record Q1 profit. The stock opened at ₹769.90 compared to the previous close of ₹769.90 on Monday, and touched an intraday high of ₹786.85 before settling at ₹769.90 by close, representing a 3.82% gain for the day. According to reports from Live Mint, the sustained rally has been driven by strong investor confidence following the company's exceptional quarterly results. The stock has now extended its winning streak to 12 consecutive trading sessions, demonstrating exceptional momentum in the current market environment.
The clean-tech company delivered exceptional financial performance for Q1 2026, with consolidated net profit increasing 27% year-on-year to ₹228 crore for the quarter ended June 30. As reported by Live Mint, this compares to ₹179.36 crore in the corresponding quarter of the previous financial year. Consolidated revenue rose 28% year-on-year to ₹1,432 crore from ₹1,118 crore in the same quarter last year, marking the highest-ever quarterly revenue for the company. EBITDA jumped 33% to ₹313 crore, taking the margin to about 22%, while the company's EBITDA and profit all touched their highest-ever quarterly levels. Chairman and Managing Director Anurag Choudhary credited the numbers to a better 'product mix across our core business and continued ramp-up in speciality materials'. The company has consistently increased ROE in the last 5 years with majority of profits being added to its reserves last year.
The company has unveiled two major expansion projects totaling fresh capex of around ₹240 crore across two strategic initiatives. According to Live Mint, the bigger project involves converting 6,000 tonnes a year of existing carbon black capacity into super speciality carbon black at a cost of ₹170 crore, aimed at batteries, plastics and coatings. The other project is a ₹70 crore facility to make carbon nanotubes, used in lithium-ion batteries and electronics, targeted for commissioning in the January-March quarter of 2027. Additionally, the company has flagged plans to expand anthraquinone and carbazole production, a set of speciality chemicals used in dyes and downstream industries, though it hasn't put a firm number on that spend yet. The company has spent 1.38% of its operating revenues towards interest expenses and 4.16% towards employee cost in the year ending March 31, 2026.
Despite the strong quarterly performance, market analysts are cautious about the stock's valuation. ICICI Securities has issued a 'Hold' rating with a target price of ₹720, suggesting that while the company's fundamentals remain strong, current valuations leave little room for error. However, The Economic Times reports that experts are now urging buying the stock with a target set at ₹800 levels in the next few weeks. The stock has demonstrated exceptional long-term performance, delivering over 17% returns in a week and over 62% gains on a year-to-date basis. As reported by Live Mint, the stock has given 54.52% gains in a year and multibagger returns of 459% in three years and 1,416% in five years. The stock has a market cap of ₹39,699.86 crore and ranks 5th within the Chemicals sector. The stock has a PE ratio of 48.61 and PB ratio of 8.16, with the stock showing a weekly stochastic crossover on July 17, 2026, which historically indicates an average price gain of 14.04% within 7 weeks based on data from the last 10 years.
